ArticlePharmaceuticals (Basel, Switzerland)2021

In Silico Screening and In Vivo Evaluation of Potential CACNA2D1 Antagonists as Intraocular Pressure-Reducing Agents in Glaucoma Therapy.

Hanxuan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.